July 13, 2012
/PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), today announced that its Board of Directors has declared a quarterly cash dividend of
per share. The dividend is payable
August 8, 2012
to stockholders of record as of
, 2012. In January, 2010, the Company announced the initiation of a cash dividend program and has subsequently paid ten consecutive quarterly dividends.
"The Company's Board of Directors and management team believe that the payment of cash dividends allows shareholders to participate directly in the Company's success" stated
, Chairman and Chief Executive Officer of The Female Health Company. "The Company's profitability has generated cash from operations that exceeds the Company's capital spending requirements, and the Company remains debt free. We believe that utilizing some of this excess cash flow to pay a higher rate of cash dividends is in the best interests of our shareholders."
Any future quarterly dividends and the record date for any such dividend must be approved each quarter by the Company's Board of Directors and announced by the Company. Payment of future dividends is at the discretion of the Board of Directors, which will base its decisions on operating cash flows, capital spending and other cash requirements, and other factors that may affect whether or not it believes the continued payment of dividends is in the best interests of the Company and its shareholders.
About The Female Health Company
The Female Health Company, based in
, manufactures and markets the
FC2 Female Condom® (FC2),
which is available in the U.S. and in about 130 other countries globally. The Company owns certain worldwide rights to the
FC2 Female Condom
®, including patents that have been issued in the U.S., the European
The People's Republic of China
and the African Regional Intellectual Property Organization (ARIPO), which includes
, United Republic of
and Zimbabwe. FC2 patent applications are pending in various countries.
The FC2 Female Condom®
is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.